PHASE I STUDY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS USING SCH58500

使用 SCH58500 对腹膜癌患者进行的 I 期研究

• 批准号: 6118455
• 负责人: DENNIS J SLAMON
• 金额: $ 0.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118455
• 关键词: antibody; carcinoma; clinical research; clinical trial phase I; gene mutation; human subject; human therapy evaluation; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; ovary neoplasms; peritoneum neoplasm; tumor suppressor genes

Up to 80% of ovarian cancer patients have tumors demonstrating p53 mutation. Antibodies to p53 are found in high numbers in patients with ovarian tumors. There was a high correlation of this finding with the presence of mutation for the p53 gene. In addition, the specificity was high (approaching 100% for ovarian cancer) but the sensitivity was quite low (approximately 15% for ovarian cancer). The incidence of p53 mutation has been correlated with the degree of malignant potential and was more commonly found in ovarian carcinoma.

高达80%的卵巢癌患者的肿瘤表现出p53突变。 在卵巢肿瘤患者中发现大量p53抗体。 这一发现与p53基因突变的存在高度相关。 此外，特异性高（卵巢癌接近100%），但敏感性相当低（卵巢癌约为15%）。 p53基因突变的发生率与卵巢癌的恶性程度有关，且在卵巢癌中更为常见。